MetaVia (MTVA) Competitors $0.79 -0.02 (-2.48%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock MTVA vs. GBIO, CALC, DARE, KALA, EGRX, TENX, TPST, CARA, GDTC, and PULMShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Generation Bio (GBIO), CalciMedica (CALC), Daré Bioscience (DARE), KALA BIO (KALA), Eagle Pharmaceuticals (EGRX), Tenax Therapeutics (TENX), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), CytoMed Therapeutics (GDTC), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Generation Bio CalciMedica Daré Bioscience KALA BIO Eagle Pharmaceuticals Tenax Therapeutics Tempest Therapeutics Cara Therapeutics CytoMed Therapeutics Pulmatrix Generation Bio (NASDAQ:GBIO) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Do analysts prefer GBIO or MTVA? Generation Bio presently has a consensus target price of $7.33, indicating a potential upside of 1,881.45%. MetaVia has a consensus target price of $7.50, indicating a potential upside of 849.61%. Given Generation Bio's higher possible upside, research analysts plainly believe Generation Bio is more favorable than MetaVia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Generation Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to GBIO or MTVA? In the previous week, MetaVia had 5 more articles in the media than Generation Bio. MarketBeat recorded 5 mentions for MetaVia and 0 mentions for Generation Bio. Generation Bio's average media sentiment score of 0.00 beat MetaVia's score of -0.30 indicating that Generation Bio is being referred to more favorably in the media. Company Overall Sentiment Generation Bio Neutral MetaVia Neutral Do insiders & institutionals believe in GBIO or MTVA? 95.2% of Generation Bio shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 21.8% of Generation Bio shares are held by company insiders. Comparatively, 1.1% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, GBIO or MTVA? MetaVia has lower revenue, but higher earnings than Generation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneration Bio$24.56M1.01-$126.61M-$1.08-0.34MetaViaN/AN/A-$12.47MN/AN/A Which has more risk and volatility, GBIO or MTVA? Generation Bio has a beta of 2.76, suggesting that its share price is 176% more volatile than the S&P 500. Comparatively, MetaVia has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Does the MarketBeat Community prefer GBIO or MTVA? Generation Bio received 44 more outperform votes than MetaVia when rated by MarketBeat users. However, 100.00% of users gave MetaVia an outperform vote while only 72.73% of users gave Generation Bio an outperform vote. CompanyUnderperformOutperformGeneration BioOutperform Votes4872.73% Underperform Votes1827.27% MetaViaOutperform Votes4100.00% Underperform VotesNo Votes Is GBIO or MTVA more profitable? MetaVia has a net margin of 0.00% compared to Generation Bio's net margin of -782.86%. Generation Bio's return on equity of -104.85% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets Generation Bio-782.86% -104.85% -49.54% MetaVia N/A -189.12%-122.31% SummaryGeneration Bio beats MetaVia on 10 of the 14 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.84M$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E RatioN/A8.4026.7219.60Price / SalesN/A258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book0.236.416.764.50Net Income-$12.47M$143.73M$3.23B$248.40M7 Day Performance15.38%0.35%0.41%-1.00%1 Month Performance-2.85%2.05%9.12%10.72%1 Year PerformanceN/A-0.65%18.73%9.00% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia1.5633 of 5 stars$0.79-2.5%$7.50+849.6%N/A$6.84MN/A0.008GBIOGeneration Bio3.6793 of 5 stars$0.39-3.5%$7.33+1,790.0%-88.7%$26.35M$24.56M-0.18150CALCCalciMedica2.0117 of 5 stars$1.86-0.2%$18.00+869.8%-68.8%$26.25MN/A-1.7430Gap UpDAREDaré Bioscience1.3984 of 5 stars$2.89flat$12.00+315.2%-39.6%$25.58M$9,784.00-4.8930KALAKALA BIO3.0739 of 5 stars$3.95-0.1%$15.00+280.2%-37.5%$25.45M$3.89M-0.3230Negative NewsAnalyst ForecastEGRXEagle PharmaceuticalsN/A$1.94flatN/A-52.8%$25.20M$257.55M0.00100Gap UpTENXTenax Therapeutics1.8926 of 5 stars$5.99-0.3%$17.50+192.4%+71.4%$24.83MN/A-2.419TPSTTempest Therapeutics1.9586 of 5 stars$6.68-0.3%$30.00+349.0%-85.2%$24.61MN/A-4.3720Gap DownCARACara Therapeutics1.5904 of 5 starsN/A$72.00+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeGDTCCytoMed Therapeutics1.4774 of 5 stars$2.22-0.5%$5.00+125.3%+5.3%$24.28M$69,501.000.00N/AGap UpPULMPulmatrix0.5368 of 5 stars$6.53+0.5%N/A+228.6%$23.88M$7.81M-2.4820Analyst ForecastGap Up Related Companies and Tools Related Companies GBIO Alternatives CALC Alternatives DARE Alternatives KALA Alternatives EGRX Alternatives TENX Alternatives TPST Alternatives CARA Alternatives GDTC Alternatives PULM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
